GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Lisdexamfetamin, exklusive Hartkapseln/Kapseln mit der Packungsgröße 30 Stück

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

January 31, 2028
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Contract not excluding drug discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V), by way of an open-house model for the active ingredient lisdexamfetamine, excluding hard capsules/capsules with a pack size of 30 pieces.

This is one of 1,400 active Germany Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedDecember 04, 2025
Procurement stageActive solicitation
Response dueJanuary 31, 2028
StatusOpen — accepting responses
TranslationTranslated from German by GlobalGov’s translation pipeline
Official sourceView original notice
Last verifiedAugust 10, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Related Opportunities in Germany

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Brodalumab, ATC L04AC12
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Amifampridin, ATC N07XX05
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for medicinal products containing the active ingredient omalizumab (ATC Code: R03DX05).
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Fluorouracil, ATC D11AF05
Germany – Pharmaceutical products – Abschluss nicht exklusiver Rabattverträge gemäß §§ 130a Abs. 8/130c Abs. 1 SGB V zu Arzneimitteln mit dem Wirkstoff Imiquimod (D06BB10) im Rahmen eines sogenannten Open-House-Modells.
Germany – Pharmaceutical products – Open house drug discount contracts for the active ingredient flecainide, ATC C01BC04
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Febuxostat (ATC-Code nach WHO: M04AA03)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Posaconazol (ATC-Code nach WHO: J02AC04)

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.